Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Sujata Patil, PhD

Associate Attending Biostatistician

Sujata Patil, PhD

Office Phone

646-888-8254

Education

University of Michigan

Current Research Interests

Dr. Patil’s biostatistical research interests are in longitudinal data analysis, survival analysis, clinical trial design, analysis of incomplete data, measurement error models, and Bayesian methods. Dr. Patil uses these methods routinely in her clinical collaborations with oncologists and surgeons in the Genitourinary, Breast, and Colorectal Surgery Services.  Dr. Patil’s current methodologic work is in two areas: developing approaches to compare cumulative risk distributions of two events; and how to design studies where there are competing events. In completed work, she has examined stage migration in metastatic renal cell carcinoma over the last four decades in internal and external datasets. Dr. Patil serves as a regular lecturer for the Department of Surgery Clinical Research Methods Lecture Series and the K30 Clinical Trial Symposium.  She also serves on Research Council, MSKCC’s scientific review committee for all human subjects’ studies.

Publications

Selected peer-reviewed publications:


  1. Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 2010 Jan 15;116(2):347-54. PubMed [PMID:19921736].

  2. Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, Atkins M, Bukowski R, Motzer RJ. Improvement in Overall Survival in Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Dataset of Clinical Trials. J Urol. 2012 Oct 17. doi:pii: S0022-5347(12)04483-7. 10.1016/j.juro.20108.026. [Epub ahead of print]

  3. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ.Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib versus interferon-alfa, Br J Cancer. 2012 May 8;106(10):1587-90. doi: 10.1038/bjc.2012.149.

  4. Blinder V, Eberle C, Patil S, Gany FM, Bradley CJ. Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. Health Aff (Millwood). 2017 Feb 1;36(2):274-281. doi: 10.1377/hlthaff.2016.1196. PubMed [PMID:28167716].

  5. Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ: Analysis of 2996 Women Treated With Breast-conserving Surgery for 30 Years. Ann Surg. 2015 Oct;262(4):623-31. doi: 10.1097/SLA.0000000000001454. PubMed [PMID:26366541].

For a complete list of publications:

http://www.ncbi.nlm.nih.gov/sites/myncbi/sujata.patil.1/bibliography/40682555/public/?sort=date&direction=ascending